H.C. Wainwright analyst Brandon Folkes raised the firm’s price target on Omeros (OMER) to $40 from $20 and keeps a Buy rating on the shares. The firm cites the approval of Yartemlea for hematopoietic stem cell transplant-associated thrombotic microangiopathy for the target boost. The analyst views the approval as a “critical inflection point” for Omeros.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OMER:
- Omeros call volume above normal and directionally bullish
- D. Boral Capital notes Omeros’ YARTEMLEA FDA win, maintains Buy rating
- Omeros: YARTEMLEA Approval and Novo Nordisk Partnership Drive Re‑Rating Potential and Support Buy Rating
- H.C. Wainwright says Yartemlea approval ‘significant validation’ of Omeros value
- Omeros trading resumes